Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout

Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout

Source: 
Fierce Pharma
News Tags: 
snippet: 

Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market—and to add blockbuster sales to a portfolio that’s at the heart of Takeda’s $62 billion buyout.